Quality of life of 5–10 year breast cancer survivors diagnosed between age 40 and 49

Health and Quality of Life Outcomes

Stephen Taplin²  Diana SM Buist³  Deborah Casso¹ 

[1] Center for Health Studies, Group Health Cooperative, 1730 Minor Ave., Suite 1600, Seattle, WA, 98101, USA;Applied Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, EPN 4005, 6130 Executive Blvd- MSC 7344, Bethesda, MD, USA;Department of Epidemiology, University of Washington, Seattle, WA, USA

关键词: quality of life;    long-term survivors;    breast cancer;   

Others  :  1216964
DOI  :  10.1186/1477-7525-2-25

 received in 2004-02-06, accepted in 2004-05-18,  发布年份 2004

【 摘 要 】

Background

The purpose of this report is to examine the correlates of quality of life (QOL) of a well-defined group of long-term breast cancer survivors diagnosed between the ages of 40 and 49.

Methods

Women were eligible if they were diagnosed with invasive breast cancer or ductal carcinoma in situ 5 to 10 years before June 30, 1998 and were enrolled at Group Health Cooperative, a health maintenance organization in western Washington State. A questionnaire was mailed to 290 women; 216 were included in this analysis. The questionnaire included standardized measures of QOL [e.g., the Cancer Rehabilitation Evaluation System (CARES-SF) and SF-36] as well as general demographic and medical information. ANOVA and logistic regression were used to estimate correlates of self-reported QOL.

Results

The mean age at diagnosis was 44.4 years, and the average time since diagnosis was 7.3 years. Women reported high levels of functioning across several standardized QOL scales; mild impairment was found on the CARES-SF Sexual Scale. The presence of breast-related symptoms at survey, use of adjuvant therapy, having lower income, and type of breast surgery were significantly associated with lower QOL 5 to 10 years post-diagnosis on one or more of the scales.

Conclusions

Our results emphasize that younger long-term survivors of breast cancer have a high QOL across several standardized measures. However, the long-term consequences of adjuvant therapy and the management of long-term breast-related symptoms are two areas that may be important for clinicians and women with breast cancer in understanding and optimizing long-term QOL.

【 授权许可】

   
2004 Casso et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 参考文献 】

• [1]Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK, eds: [http://seer.cancer.gov/csr/1973_1999/] webciteSEER Cancer Statistics Review, 1973–1999. National Cancer Institute. Bethesda, MD; accessed December 26, 2002
• [2]Jemal A, Thomas A, Murray T, Thun M: Cancer Statistics, 2002. CA Cancer J Clin 2002, 52:23-47.
• [3]Ganz PA, Coscarelli A, Fred C, Kahn B, Polinsky ML, Petersen L: Breast cancer survivors: psychosocial concerns and QOL. Breast Cancer Research and Treatment 1996, 38:183-199.
• [4]Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE: Life after breast cancer: understanding women's health related QOL and sexual functioning. J Clin Oncol 1998, 16:501-14.
• [5]Arora NK, Gustafson DH, Hawkins RP, McTavish F, Cella DF, Pingree S, Mendenhall JH, Mahvi DM: Impact of surgery and chemotherapy on the QOL of younger women with breast carcinoma: a prospective study. Cancer 2001, 92:1288-98.
• [6]Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR: Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 2002, 94:39-49.
• [7]Dorval M, Maunsell E, Deschenes L, Brisson J, Masse B: Long-term quality of life after breast cancer: comparison of 8-year survivors with population controls. J Clin Oncol 1998, 16:487-94.
• [8]Ashing-Giwa K, Ganz PA, Peterson L: Quality of life of African-American and white long term breast carcinoma survivors. Cancer 1999, 85:418-26.
• [9]Dow KH, Ferrell BR, Leigh S, Ly J, Gulasekaram P: An evaluation of the quality of life among long-term survivors of breast cancer. Breast Cancer Res Treat 1996, 39:261-73.
• [10]Taplin SH, Mandelson MT, Anderman C, White E, Thompson RS, Timlin D, Wagner EH: Mammography diffusion and trends in late-stage breast cancer: evaluating outcomes in a population. Cancer Epidemiol Biomarkers Prev 1997, 6:625-31.
• [11]Dillman DA: Mail and Telephone Surveys : The Total Design Method. New York: Wiley; 1978.
• [12]Armstrong BK, White E, Saracci R: Principles of exposure measurement in epidemiology. In In Monographs in Epidemiology and Biostatistics. Volume 21. New York: Oxford University Press; 1994.
• [13]Velicer CM, Taplin SH: Genetic testing for breast cancer: where are health care providers in the decision process? Genet Med 2001, 3:112-9.
• [14]Coscarelli-Schag CA, Ganz PA, Heinrich RL: Cancer rehabilitation evaluation system – short form (CARES-SF): a cancer specific rehabilitation and quality of life instrument. Cancer 1991, 68:1406-1413.
• [15]Ware JE, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care 1992, 30:473-483.
• [16]Ware JE, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A: Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: Summary of results from the Medical Outcomes Study. Med Care 1995, 33:AS264-AS279.
• [17]Radloff LS: The CES-D Scale: A self-report depression scale for research in the general population. Appl Psychol Measur 1977, 1:385-401.
• [18]American Joint Committee on Cancer: Manual for Staging of Cancer. 4th edition. Philadelphia (PA): Lippincott; 1992.
• [19]Von Korff M, Wagner EH, Saunders K: A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992, 45:197-203.
• [20]Taplin SH, Barlow W, Urban N, Mandelson MT, Timlin DJ, Ichikawa L, Nefcy P: Stage, age or comorbidity and the direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995, 87:417-26.
• [21]Barlow WE, Taplin SH, Yoshida CK, Buist DS, Seger D, Brown M: Cost comparison of mastectomy versus breast-conserving therapy for early-stage breast cancer. J Natl Cancer Inst 2001, 93:447-55.
• [22]Stata Corporation: Stata Statistical Software: Release 6.0. College Station, TX: Stata Corporation 1999.
• [23]Bernabei R, Gambassi G, Lapane K, Landi F, Gatsonis C, Dunlop R, Lipsitz L, Steel K, Mor V: Management of pain in elderly patients with cancer. SAGE Study Group. Systematic Assessment of Geriatric Drug Use via Epidemiology. JAMA 1998, 279:1877-82.
• [24]Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ: Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994, 330:592-6.
• [25]Daut RL, Cleeland CS: The prevalence and severity of pain in cancer. Cancer 1982, 50:1913-8.
• [26]Berkman CS, Gurland BJ: The relationship among income, other socioeconomic indicators, and functional level in older persons. J Aging Health 1998, 10:81-98.